John C.M. Farquhar,CEO of Heartflow,Inc. (NASDAQ: HTFL), sold 22,562 shares on July 10, 2026. Average price: $27.75, bringing in $626,095.50 . He still holds 435,373 shares, worth about $12.08 million.
This sale cuts his holdings by 4.93%. It was part of a pre-set Rule 10b5-1 plan,a legal way for insiders to sell shares without insider trading accusations.
Recently, Farquhar offloaded 38,900 shares on June 24,2026,at $35.00 each,totaling $1.36 million. Earlier in June, another 22,562 shares went at $28.50,netting $643,017. He also sold 22,562 shares on May 11, 2026, at $29.12, for $657,005.44.
On July 13, 2026, Heartflow's stock dipped $0.56,closing at $26.16. Trading volume hit 1,054,641 shares, well below average of 2,066,071. Over past year, HTFL ranged from $20.13 to $41.22 .
Heartflow announced quarterly earnings on May 14,2026, posting $0.16 per share loss, beating forecasts of -$0.24 . Revenue reached $52.59 million, up 41.3% from last year. Analysts expect annual earnings per share of -0.82.
Analyst opinions on Heartflow are mixed. Freedom Capital upgraded to “strong-buy” on June 30,while Weiss Ratings downgraded to “sell (e+)” on July 8. Canaccord Genuity Group cut target price from $43.00 to $37.00,keeping a “buy” rating . JPMorgan Chase & Co. dropped price target from $40.00 to $35.00, calling it “overweight.” Heartflow's average rating: “Moderate Buy” with $37.00 target .
Big investors are shuffling their Heartflow stakes. Handelsbanken Fonder AB bought in for about $910,000 in Q2 . Bank of America Corp DE upped its stake by 28.8%,now holding 111,702 shares worth $2.72 million. Janus Henderson Group PLC boosted its holding by 152.0%, owning 2,180,976 shares valued at $53.06 million after adding 1,315,416 shares.
Heartflow is known for its non-invasive coronary artery disease diagnostics. Its tech converts coronary CT angiography data into a 3D model,helping doctors spot problematic lesions without surgery .
